Potential PET tracers for imaging of tumor-associated macrophages

Bruna Fernandes1,2, Paula Kopschina Feltes1, Carolina Luft3,4, Luiza Reali Nazario1, Cristina Maria Moriguchi Jeckel2, Ines F. Antunes1, Philip H. Elsinga1 and Erik F. J. de Vries1*

Abstract
The increasing incidence of cancer over the years is one of the most challenging problems in healthcare. As cancer progresses, the recruitment of several immune cells is triggered. Infiltration of tumor-associated macrophages (TAMs) is correlated with poor patient prognosis. Since TAMs constitute a big portion of the tumor mass, targeting these cells seems to be an attractive approach for cancer immunotherapy. Additionally, TAM assessment using non-invasive imaging techniques, such as positron emission tomography (PET), might provide a better understanding of the role of TAMs in cancer, and a means for tumor profile characterization, patient selection for individualized immunotherapy and treatment monitoring. Imaging of TAMs using PET tracers is still in its infancy. TAMs have several characteristics that could be exploited as potential targets for imaging. Various PET tracers for these TAM biomarkers have been developed, although often in the context of (neuro)inflammatory diseases rather than cancer. Since macrophages in inflammatory diseases express similar biomarkers as TAMs, these PET tracers could potentially also be applied for the assessment of TAMs in the tumor microenvironment. Therefore, the present review provides an overview of the TAM biomarkers, for which potential PET tracers are available and discusses the status of these tracers.

Keywords: Tumor-associated macrophages, Tumor microenvironment, M2-like, M1-like, PET imaging

Background
In the last decades, an exponential growth in new cases of cancer has been reported worldwide. Cancer is a leading cause of death and limits the increase in life expectancy in all countries of the world (Pilleron et al. 2019). In 2020, 19.3 million new cases were reported. The elderly population (65+ years old) accounted for 51.6% of new cases, whereas adults under 65 years old were responsible for 48.4%. Predictions expect a global cancer burden of approximately 28 million cases for the year of 2040, representing a 47% increase compared to 2020. The most common cancer types reported in 2020 were breast cancer, lung cancer, colorectum cancer, prostate cancer, stomach cancer, and liver cancer (Sung et al. 2021). Interestingly, all these cancers may present infiltration of macrophages (Skytthe et al. 2020; Quail and Joyce 2017).
Macrophages play a crucial role in the innate and adaptive immune system (Zhou et al. 2020). They express a broad phenotypic heterogeneity and functional diversity. The activation of macrophages is a stress-dependent process. Macrophages of the M0 phenotype (non-polarized) turn into the M1 phenotype (classically activated), when exposed to e.g. interferon-gamma (IFN-γ), tumor necrosis factor (TNF) or lipopolysaccharide (LPS) (Ivashkiv 2018; Russell et al. 2019). Pro-inflammatory mediators such as reactive oxygen species (ROS), interleukin-12 (IL-12), IL-1β, TNF-α, IL-6, inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), among others, are released by these activated macrophages. In contrast, alternative activation by exposure to interleukin-4 (IL-4) and/or interleukin-13 (IL-13) results in the M2 phenotype, which is characterized by an increase in the release of anti-inflammatory mediators, such as interleukin-10 (IL-10) (Russell et al. 2019; Jung et al. 2019). Some authors have described that the phenotype shift goes beyond the plasticity dichotomy, where macrophages may even present two phenotypes at the same time depending on the moment of the injury, becoming the newly hypothesized M3 phenotype (Chistiakov et al. 2018; Malyshev and Malyshev 2015).

Besides the central role in tissue repair and systemic inflammation and immunity, macrophages play a crucial role in the tumor microenvironment (TME). Infiltrated macrophages in the TME, the so-called tumor-associated macrophages (TAMs), display broad phenotypic plasticity and can not only promote tumor regression (M1-like TAM), but also tumor progression (M2-like TAM). Since TAMs can represent approximately 30–50% of the tumor mass and trigger several factors that promote tumor growth, invasion, metastasis, and drug resistance (Quail and Joyce 2017; Malyshev and Malyshev 2015; Cendrowicz et al. 2021; Poh and Ernst 2018), they have been considered a potential target for early cancer detection and treatment (Quail and Joyce 2017). TAM-targeted therapies have gained considerable attention in the last years, resulting in the emergence of new drugs that can modulate and recalibrate the immune system within the TME. Therapeutic approaches such as depletion (e.g. with CSF-1R inhibitors), repolarization (e.g. with arginase inhibitors), inhibition of TAMs recruitment (e.g. inhibition of the CCR2 axis), and immune-checkpoint blockades (e.g. with PD-1 inhibitors) could improve treatment outcome (Li et al. 2021). Additionally, assessment of the infiltration levels and phenotype of TAMs might be helpful for the selection of the most suitable immune therapy (single or combined) for the patient and the evaluation of treatment response.

The present article aims to summarize the main TAM biomarkers that could be used as target for non-invasive prognosis and therapy response monitoring by means of Positron Emission Tomography (PET). PET is a state-of-the-art imaging technique that can provide in vivo insights in physiological and molecular processes, provided that a suitable imaging probe is available for the target of interest. The overview is limited to targets on TAM, for which PET tracers are already available, or in development.

Main text

Macrophages and the tumor microenvironment (TME)

Primary tumors and metastases are complex systems composed of neoplastic cells, extracellular matrix, and non-neoplastic cells, which include resident mesenchymal
support cells, endothelial cells, and infiltrated immune cells (Gonzalez et al. 2018). The main immune cells involved in the initial inflammatory response are the neutrophils and macrophages, as well as dendritic, NK, and lymphoid cells (Pilleron et al. 2019; Cendrowicz et al. 2021; Mukherjee et al. 2019). When immune cell recruitment continues, an exacerbated activation occurs, leading to an unbalanced microenvironment, which leads to chronic inflammation and tumor growth (Chistiakov et al. 2018). During tumor development, angiogenesis and increased permeability of the vessels facilitate the supply of nutrients and oxygen to the TME (Chistiakov et al. 2018; Ngambenjawong et al. 2017; Murphy and Weaver 2016). TME is a dynamic and intricate system infiltrated not only by innate, but also by adaptive immune cells (Chistiakov et al. 2018; Murphy and Weaver 2016). T and B lymphocytes, NK cells, dendritic cells, macrophages, neutrophils, and myeloid-derived suppressor cells constitute the main immune cells in the TME that, in combination with other cells in the tissue, such as fibroblast, adipocytes, and vascular endothelial cells, trigger tumor progression (Galli et al. 2020).

TAMs can present up to 50% of tumor mass in solid tumors (Poh and Ernst 2018; Vinogradov et al. 2014). These cells play a key role in tumor progression, angiogenesis, and are associated with immunosuppression and the activation of a chronic inflammatory response (Poh and Ernst 2018). Thus, high levels of TAMs in the TME are usually associated with a poor prognosis of the disease (Poh and Ernst 2018; Chen et al. 2019).

**TAM polarization**

The polarization of the macrophages into the M1 and M2 phenotypes is generally associated with the stage of cancer (Fig. 1). The pro-inflammatory phenotype (M1) is...
often found in early stages, regressing or dead tissue-containing tumors (Boutilier and Elsawa 2021). These macrophages are responsible for the release of pro-inflammatory cytokines, such as INF-γ and TNF-α, and the activation of T cells as a tumoricidal mechanism (Boutilier and Elsawa 2021; Chen et al. 2018). M1 polarization through the macrophage migration inhibitory factor can also lead to tumor death by regulating both cell proliferation and invasiveness, activating the release of TNF-α and IL-1β (Poh and Ernst 2018; Chen et al. 2018). In contrast, tumors in more advanced stages mainly contain macrophages of the M2 phenotype, which induce a pro-tumoral state (tumor progression) (Boutilier and Elsawa 2021). Although the polarization mechanism of TAMs is not yet fully understood, studies show that a hypoxic environment and expression of hypoxia-inducible factors 1-α and 2-α are associated with increased expression of genes related to M2 polarization (Murphy and Weaver 2016). In addition, the secretion of anti-inflammatory cytokines by tumor cells is also an important factor in the polarization of M2 TAMs. The anti-inflammatory status characterized by M2 macrophages is related to immunosuppression (T-reg cells attraction), increased expression of programmed death-ligand 1 (PD-L1) on the surface of macrophages, the release of transforming growth factor-β (TGF-β), and secretion of cytokines such as IL-4 and IL-13 (Wang and DuBois 2015). Therefore, increased levels of M2-phenotype have been associated with pro-tumorigenic inflammation, leading to poor outcomes (Ngambenjawong et al. 2017).

**PET imaging and TAMs**

PET imaging could be a useful tool for characterization of TAM polarization, depletion, and recruitment (inhibition). Noteworthy, most studies using PET tracers targeting receptors present on TAMs were conducted in preclinical animal models (Table 1), whereas just a few tracers were tested in patients. The majority of PET imaging studies targeting receptors present on TAMs were performed in animal models for (neuro) inflammatory diseases, rather than tumor models. Nonetheless, these studies can provide insight into the binding properties of ligands to receptors or enzymes of interest, which can be translated to studies with tumor models or cancer patients.

**Targets mainly expressed by TAMs**

**CSF-1R**

Colony Stimulating Factor 1 receptor (CSF-1R) is a member of the tyrosine kinase receptor family, mainly expressed on macrophages (Zhang et al. 2020). The CSF-1R plays an important role in the macrophage's proliferation and differentiation, which can be stimulated by tumor cells via CSF1 secretion (CSF-1R ligand) (Fischer et al. 2009). The CSF-1R seems to be a potential target for imaging of macrophages/microglia, since this receptor is highly expressed on these cells in the TME and at sites of inflammation (Cendrowicz et al. 2021). Several studies have shown that the CSF-1R can be expressed by macrophages of both the M1 and M2 phenotype (Fischer et al. 2009; Cannarile et al. 2017), although it is still inconclusive in what phenotype it is predominantly expressed. High expression of CSF-1R in tumors has been related to poor prognosis.

Several studies have reported inhibition of the CSF-1R as a potential strategy for TAM depletion (Noy and Pollard 2014; Valero et al. 2021). For instance, the CSF-1R inhibitor PLX3397 was evaluated in a phase 1 clinical trial in patients with
tenosynovial giant-cells tumors. After 4 months of treatment, 11 of 14 patients had a mean decrease in tumor volume score of 61%. The remaining 3 patients had stable disease (Tap et al. 2015). In a preclinical study conducted by Pyonteck et al., the

| Target | Macrophage phenotype | Radiotracer | Species | Disease (model) | References |
|--------|----------------------|-------------|---------|-----------------|------------|
| CD206  | M2                   | [18F]FDM    | Rabbit | Atherosclerosis model | Tahara et al. (2014) |
|        |                      | [18F]FB-anti-MMR-sdAb | Mouse | Lung cancer xenograft model | Blykers et al. (2015) |
|        |                      | [68Ga]NOTA-MSA | Mouse | Atherosclerosis model | Kim et al. (2016) |
|        |                      | [68Ga]NOTA-anti-MMR-Nb | Mouse | Atherosclerosis model | Varasteh et al. (2019) |
|        |                      | [68Ga]Ga-NOTA-anti-MMR-sdAb | Mouse | Lung cancer xenograft model | Xavier et al. (2019) |
| CD163  | M2                   | [68Ga]ED2   | Rat     | Arthritis model | Eichendorff et al. (2015) |
| Arginase | M2                 | [18F]FMARS  | Mouse   | Prostate cancer xenograft model | Clemente et al. (2021) |
|         |                      | [18F]FBMARS | Mouse   | Prostate cancer xenograft model | Clemente et al. (2021) |
| CSF-1R | M1 and M2            | [11C]AZ683  | Rat, non-human primate | Healthy | Tansey et al. (2018) |
|         |                      | [11C]CFPCC  | Mouse, non-human primate | Neuroinflammation model (LPS) | Horti et al. (2019), Zhou et al. (2021) |
|         |                      | [11C]GW2580 | Mouse, non-human primate | Neuroinflammation mouse model (LPS) and health non-human primates | Zhou et al. (2021) |
| CD68   | M1 and M2            | [64Cu]CD68-Fc | Mouse | Atherosclerosis model | Bigalke et al. (2014) |
| CCR2   | M1 and M2            | [64Cu]DOTA-ECLI | Rat | Abdominal aortic aneurysm model | English et al. (2020) |
|         |                      | [64Cu]Cu@CuOx-ECLI | Mouse | Pancreatic ductal adenocarcinoma model | Zhang et al. (2021) |
| Folate receptor | M1 and M2 | [18F]Jb | Mouse | Healthy | Wagner et al. (2021) |
|         |                      | [68Ga]NOTA-folate | Mouse | KB xenograft model | Brand et al. (2017) |
|         |                      | [18F]AlF-NOTA-folate-PEG12 | Mouse | KB xenograft model | Chen et al. (2017) |
|         |                      | [18F]fluoro-PEG-folate | Mouse | Rheumatoid arthritis model | Chandrupatla et al. (2018) |
|         |                      | [18F]AlF-NOTA-folate | Human | Rheumatoid arthritis | Verweij et al. (2020) |
|         |                      | [18F]AzaFol | Mouse | Atherosclerosis model | Schniöler et al. (2018) |
|         |                      | [18F]AZaFol | Human | Lung fibrosis model | Schniöler et al. (2019) |

sdAb: single-domain antibody; Nb: nanobody; CSF-1R: Colony stimulating factor 1 receptor; CD: cluster of differentiation; CCR2: C–C chemokine receptor type 2; KB: human epithelial cancer cell; Fc: fragment crystallizable region; LPS: lipopolysaccharides; 6b: 2-[4-(5-Fluoropentoxy)phenyl]-N-(4-(N-methyl-N-[tetrahydro-2H-pyran-4-yl]aminomethyl)phenyl)-6,7-dihydro-5H-benzof[7]annulene-8-carboxamide
compound BLZ945 improved long-term survival in a glioblastoma mice model, with 64.3% of the mice surviving up to the 26 weeks end-point (Pyonteck et al. 2013). Therefore, imaging the CSF-1R expression on macrophages might help the physician to select patients for CSF-1R targeting therapy, and monitoring of the patient therapy response. Besides these applications, PET imaging of CSF-1R could also be useful for the evaluation of new specific and sensitive CSF-1R inhibitors that have been emerged as potential TAM-therapies, as well as a better understanding of CSF-1R mechanisms involved in the tumor progression (Cendrowicz et al. 2021; Zhang et al. 2020; Noy and Pollard 2014). Several CSF-1R ligands, including AZ683, BL2945, PLX3397, GW2580, AZD7507, and CPPC, have been radiolabeled and tested as candidate PET tracers for CSF-1R (Fig. 2) (Tanzey et al. 2018; Horti et al. 2019). Tanzey et al. used $^{11}$C]AZ683 for imaging the brain of healthy rats and non-human primates (Tanzey et al. 2018). Even though the tracer seemed to be a good candidate due to its high target selectivity, low plasma protein binding and suitability to be labeled with carbon-11 and fluorine-18, $^{11}$C]AZ683 when evaluated in vivo showed little brain uptake and high uptake in pituitary and thyroid glands. These findings might indicate either non-specific binding or that $^{11}$C]AZ683 might be a possible substrate for the P-glycoprotein transporter. Therefore, the authors suggested to use this tracer in
future studies in peripheric inflammation or tumor models, but no reports of such studies have been published so far.

Horti et al. conducted the first study demonstrating the selectivity of $^{[11]}\text{C}]\text{CPPC}$ for the CSF-1R on microglia in pre-clinical studies (Horti et al. 2019). The radiotracer is lipophilic enough to pass through the BBB (Log $D_{7.4} = 1.6$) and has a similar IC$_{50}$ (0.8 nM) as other CSF-1R ligands (e.g. BLZ945 1.2 nM; and PLX3397 20 nM). Studies conducted in animal models of neuroinflammation (LPS-induced) and neurodegenerative diseases (Alzheimer’s diseases; Multiple Sclerosis) indicate the tracer binds specifically to CSF-1R. Post-mortem investigations on human brain slices also show CSF-1R mediated specific binding (Valero et al. 2021). Recently, Zhou et al. developed GW2580 (IC$_{50} = 10$ nM) labeled with $^{11}$C and compared this tracer to $^{[11]}\text{C}]\text{CPPC}$ in a rodent model for neuroinflammation and in non-human primates (Tanzey et al. 2018). In the mice inflammation model, $^{[11]}\text{C}]\text{GW2580}$ showed a 1.8-fold higher uptake than $^{[11]}\text{C}]\text{CPPC}$, suggesting slightly higher sensitivity of the former tracer. Blocking studies demonstrated approximately 30% less uptake of $^{[11]}\text{C}]\text{GW2580}$ in the normal non-human primate brain after administration of unlabeled GW2580 than at baseline. On the other hand, minimal blockade of $^{[11]}\text{C}]\text{CPPC}$ uptake after administration of unlabeled CPPC was observed under normal physiological conditions. Therefore, Zhou et al. suggested that $^{[11]}\text{C}]\text{GW2580}$ might be a superior candidate tracer for imaging of CSF-1R.

None of the radiopharmaceuticals described in this section were tested in tumor models or in humans. Based on brain imaging studies in animals, $^{[11]}\text{C}]\text{GW2580}$ seems to be the most suitable PET tracer for CSF-1R, as it showed higher specific brain uptake than $^{[11]}\text{C}]\text{AZ683}$ and $^{[11]}\text{C}]\text{CPPC}$.

Scavenger receptors

The scavenger receptor family (SR-A, SR-B, SR-C, SR-D, SR-E, SR-F, SR-G, SR-H, SR-I, SR-J, SR-K, SR-L) plays a vital role in the clearance of endogenous and host molecules from the TME (PrabhuDas et al. 2017). The SR-D1, also known as CD68, is the only member of this family that can be found on monocytes and macrophages. CD68 is a transmembrane protein that participates in oxidized low-density protein (OxLDL) clearance (e.g., lipid-laden foam cells in atherosclerosis) (PrabhuDas et al. 2017) and is considered a pan-macrophage marker (PrabhuDas et al. 2017; Yang et al. 2019; Jeong et al. 2019). High expression of the CD68 marker in tumors, such as in breast, cervix, and bladder carcinoma, has been correlated with a poor prognosis (Jeong et al. 2019). Bigalke et al. labeled a CD68 antibody fragment (Fc) with Cu-64 ($^{[64]}\text{Cu}]\text{CD68-Fc}$) to detect foam cells (fat-laden M2 macrophages containing low-density lipoproteins) in an atherosclerosis model (Bigalke et al. 2014). The ApoE$^{-/-}$ mice that received a fat-rich diet showed a higher tracer uptake in the aortic arch when compared to wild-type control mice. This finding correlated well with the results from magnetic resonance imaging (R1-mapping) and ex vivo analyses, such as histology and immunostaining (Bigalke et al. 2014). Although the $^{[64]}\text{Cu}]\text{CD68-Fc}$ was used to detect foam cells in cardiovascular diseases, this tracer may also be useful for imaging of TAM.

The macrophage mannose receptor (MMR, SR-E3 subtype), also known as CD206, might be a suitable M2-specific marker (Blykers et al. 2015; PrabhuDas et al. 2017). CD206 is a C-type lectin transmembrane protein able to detect and phagocytose
pathogens (PrabhuDas et al. 2017). Radiotracers for CD206 (Fig. 3), such as $[^{18}\text{F}]$FDM, $[^{68}\text{Ga}]$NOTA-MSA, and $[^{68}\text{Ga}]$NOTA-anti-MMR-nanobody (Nb), have been developed and studied mainly in animal models for atherosclerosis (Tahara et al. 2014; Blykers et al. 2015; Kim et al. 2016; Varasteh et al. 2019; Xavier et al. 2019). A few tracers have been tested in preclinical tumor models, in particular $[^{18}\text{F}]$FB-anti-MMR-single-domain antibody (sdAb) and $[^{68}\text{Ga}]$Ga-NOTA-anti-MMR-sdAb (Blykers et al. 2015; Xavier et al. 2019). Xavier et al. demonstrated that $[^{68}\text{Ga}]$Ga-NOTA-anti-MMR-sdAb showed higher uptake in tumors, liver and spleen (organs with a high density of M2 macrophages) of wild-type tumor-bearing mice (Lewis lung carcinoma model) as compared to CD206 knock-out mice (Xavier et al. 2019). The wild-type group showed 3.54 times higher $[^{68}\text{Ga}]$Ga-NOTA-anti-MMR-sdAb uptake than the knock-out mice when expressed as tumor-to-blood ratio. Likewise, Blykers et al. observed that $[^{18}\text{F}]$FB-anti-MMR-sdAb showed significantly (ca. eightfold) lower uptake in the tumors of knock-out mice when compared to wild-type mice (Blykers et al. 2015), suggesting that the tracer binds specifically to CD206. Besides the high tumor uptake found for the anti-MMR-sdAb labeled with gallium-68 or fluorine-18, the tracers also presented high specific uptake in organs expressing MMR, such as liver, spleen, lymph nodes, and bone marrow (Blykers et al. 2015; Xavier et al. 2019). Despite $[^{18}\text{F}]$FB-anti-MMR-sdAb shows to be a potential PET tracer for CD206 receptor, dosimetry and toxicity studies still are warranted for tracer evaluation. Therefore, Xavier et al. suggested $[^{68}\text{Ga}]$Ga-NOTA-anti-MMR-sdAb for future evaluation in clinical studies, since this tracer was already demonstrated to have safe dosimetry and its labeling can easily be implemented in radiopharmacies with a $^{68}\text{Ge}/^{68}\text{Ga}$ generator.

The cysteine-rich scavenger receptors (SRCR; SR-I family), such as CD163, have been extensively studied in order to understand the M2 macrophage phenotype (Graversen and Moestrup 2015). CD163 is a transmembrane protein responsible for haptoglobin-hemoglobin (Hp-Hb) clearance. It is considered an anti-inflammatory receptor due to its capacity to clear free Hb and to promote the production of anti-inflammatory mediators (Skytte et al. 2020; Yang et al. 2019). This receptor seems to be a good target for imaging of M2-like macrophages, since several studies have reported a high density of CD163+ macrophages in the TME, which correlated with a poor prognosis (Skytte et al. 2020; Li et al. 2021). Until now, the tracers developed for this receptor were evaluated in arthritis
and atherosclerosis animal models. *Eichendorff* et al. labeled a CD163 antibody with gallium-68 ([68Ga]ED2) and showed highly selective binding to transfected CHO cells over-expressing the rat CD163 receptor. In vivo studies in a collagen-induced arthritis (CIA) rat model showed higher liver and lower spleen uptake of [68Ga]ED2 in the CIA group, when compared to healthy animals (*Eichendorff* et al. 2015). This might be explained by the immune response induced by CIA with higher infiltration of monocytes possibly derived from the spleen. Spleen contains a storage of monocytes that can be released into the circulation in peripheral inflammatory response (*Eichendorff* et al. 2015). The CIA model promotes an immunological response causing modulation of M2 polarization in the liver (Kupffer cells), spleen (splenic red pulp) and the paw. Consequently, CIA caused a 1.83-fold increase in [68Ga]ED2 uptake in the inflamed paw compared to the healthy paw. Yet, the [68Ga]ED2 uptake in the liver and spleen was much higher than in the inflamed paw. *Eichendorff* et al. hypothesized that this difference in uptake might be due to ineffective antibody penetration in the inflamed tissues due to its size. Another possible explanation is the fact that the biological half-life of large biomolecules such as antibodies (days to weeks) does not match with the physical half-life of the gallium-68 (68 min) (*Tsai* and *Wu* 2018), which precluded delayed image acquisition. The use of an antibody fragment (Fab) or small molecules like peptides instead of the entire anti-CD163 antibody might increase tissue penetration and decrease the biological half-life, allowing the radiolabeling with gallium-68. *Silva* et al. conducted a study using a novel peptide, CTHRSSVVC, labeled with indium-111 ([111In]DOTA-CTHRSSVVC) and showed high tracer uptake in the atheroma of low-density protein receptor-deficient mice ex vivo (*Silva* et al. 2016). Besides being a promising candidate for CD163 receptor imaging with single-photon emission computerized tomography (SPECT), the peptide could be labeled with a positron-emitting isotope and used for PET imaging, which offers a higher sensitivity and resolution and better quantification options than SPECT.

In summary, [64Cu]CD68-Fc seems to be a good candidate tracer for CD68, which could be used for general TAM imaging. However, this tracer has not been tested in tumor models yet. On the other hand, [68Ga]Ga-NOTA-anti-MMR-sdAb seems to be a suitable PET tracer for imaging of TAM of the M2-phenotype. This tracer was successfully tested in tumor models and presented good outcomes in dosimetry studies. Although the CD163 receptor also seems to be a good target for imaging of macrophages of the M2-phenotype, no suitable PET tracer for this target is available yet. None of the PET tracers for scavenger receptors has been evaluated in patients yet.

**CCL2/CCR2**

Chemokine (C–C Motif) ligand 2 (CCL2), also known as monocyte chemo-attractant protein-1 (MCP-1), is responsible for the recruitment of immune cells to the site of inflammation. However, when its response is exacerbated, it can lead to the development of several pathologies (*Baggiolini* 1998). In the case of tumors, the exacerbated recruitment of immune cells, especially of activated monocytes and immunosuppressive TAMs, can lead to the formation of an immune cell network in the TME that leads to tumor progression (*Hao* et al. 2020). CCL2 can also be found in the blood stream and has been proposed as biomarker for cancer diagnosis (*Tsaur* et al. 2015; *Lubowicka* et al. 2018). *Deci* et al. demonstrated that chemokine receptor type 2 (CCR2) inhibition...
with the single-chain variable fragment 58C-scFv (selected by phage display) repolarizes macrophages from M1 to M2, suggesting that CCR2 might be linked to the M2 phenotype (Deci et al. 2018). New therapeutic inhibitors of CCR2, such as carlumab and PF-04136309, have been used in clinical trials to block CCL2/CCR2 signaling, leading to inhibition of TAM infiltration, and consequently, reduction of tumor progression (Zhang et al. 2020).

Recently, PET tracers were developed for imaging of the CCR2. Wagner et al. developed the $[^{18}F]2$-[4-(5-fluoropentoxy)phenyl]-N-[4-[N-methyl-N-(tetrahydro-2H-pyran-4-yl)aminomethyl]phenyl]-6,7-dihydro-5H-benzo[7]annulene-8-carboxamide, a $^{18}$F-labeled CCR2 selective antagonist (called $[^{18}F]$6b), that showed high binding affinity to the CCR2. The tracer was stable in vitro and in vivo, and showed little defluorination and a fast uptake in the liver, spleen, lungs and kidneys of healthy mice. However, preclinical evaluation of this tracer in a pathological model has not been reported so far (Wagner et al. 2021). Another group labeled the peptide ECLi with copper-64 and used it to assess the expression of CCR2 in a rodent model of an abdominal aortic aneurysm (AAA), in which monocytes and macrophages play a critical role. The authors reported a high sensitivity and specificity for detecting CCR2$^+$ cells in the AAA model. Additionally, $[^{64}Cu]$DOTA-ECLi also demonstrated specific binding to ex vivo human AAA specimens with high expression of CCR2$^+$ cells (English et al. 2020). So far, only a few studies explored the potential of PET imaging of CCR2-expressing macrophages in tumor models. Zhang et al. used ultra-small radiolabeled copper nanoparticles, $[^{64}Cu]$Cu@CuOx, coupled with the ECLi peptide in an animal model of pancreatic ductal adenocarcinoma (PDAC) (Zhang et al. 2021). Target specificity and sensitivity was evaluated in vitro and in vivo. Firstly, PDAC cells derived from mice (KI) and human monocyte THP-1 cells were used to assess the tracer uptake. In both KI and THP-1 cells, $[^{64}Cu]$Cu@CuOx-ELCi uptake was nearly fivefold higher than uptake of the non-targeted analogue $[^{64}Cu]$Cu@CuOx. Competition with non-labeled Cu@CuOx-ELCi as blocking agent resulted in an over 80% reduction in the $[^{64}Cu]$Cu@CuOx uptake in both cell lines. In the PDAC mice model, $[^{64}Cu]$Cu@CuOx-ELCi demonstrated a threefold higher uptake than the non-targeted $[^{64}Cu]$Cu@CuOx analogue (Fig. 4) (Zhang et al. 2021).

Overall, both PET tracers based on the ELCi molecule demonstrated specific binding to CCR2, but only $[^{64}Cu]$Cu@CuOx-ELCi was tested in tumor-bearing mice. No studies with these tracers have been performed in humans. Despite the early stage in tracer development, these tracers could be a suitable candidate PET tracer for general TAM imaging, provided that the remaining qualification of the tracers is successful.

**Folate receptors**

Folate receptors (FR) are N-glycosylated proteins that can have different isoforms (FRα, FRβ, FRy, and FRδ), which are overexpressed in different cell types. FRα can be found in epithelial cells and certain cancers with epithelial origin, such as ovary, breast, bladder, epithelium, and colon (Shen et al. 2018; Sosnik 2018). FRβ is expressed by monocytes and activated macrophages (Brand et al. 2017; Kurahara et al. 2012; Puig-Kröger et al. 2009). Recently, high expression of FRβ was observed in IL-10 and CD163-expressing macrophages of the M2 phenotype (Choi et al. 2018; Newman and Maddocks 2017). FRβ expressing macrophages are not only present in the TME but also in other inflammatory
diseases, such as rheumatoid arthritis (Shen et al. 2018; Kurahara et al. 2012; Choi et al. 2018). Little information is available regarding the FRγ and FRδ subtypes, but they can be found on regulatory T cells and at low concentrations in blood, respectively (Shen et al. 2018).

Folic acid (FA) binds with high affinity to all folate receptors and is internalized by endocytosis. Folic acid is converted to tetrahydrofolate (THF) by dihydrofolate reductase (DHFR) and this step is an important target for antifolate drugs, such as methotrexate, pemetrexed, and raltitrexed (Newman and Maddocks 2017). THF is essential for one-carbon supply to the purine, methionine and thymidine synthesis, and consequently the proliferation of cells. Cancer cells can use this pathway for survival and proliferation (Newman and Maddocks 2017). Therefore, FA and FA-derivatives have been considered a potential drugs in cancer research (Brand et al. 2017; Silvola et al. 2018; Choi et al. 2018; Boss et al. 2018).

In addition to its applications in cancer therapy, imaging agents based on FA-derivatives have been developed during the last years (Fig. 5). Silvola et al. synthesized the [18F]AIF-NOTA-folate, which presented good in vivo stability (85%) and significant specific binding to the FR in the plaques in an atherosclerotic rabbit model (ca. 82%) and in an atherosclerotic mouse model (ca. 92%), as measured ex vivo with autoradiography (Silvola et al. 2018). Binding studies with [18F]AIF-NOTA-folate on human carotid endarterectomy samples stained positive for FRβ and CD68 also showed significant blocking (ca. 88%) of tracer binding, when the folate glucosamine was co-administered. Although specific binding of [18F]AIF-NOTA-folate to FR on the polarized M2 macrophage phenotype was observed in in vitro studies, specific binding to the M1 macrophage phenotype was demonstrated in atherosclerotic mice. Therefore, [18F]AIF-NOTA-folate might be a potential tracer for FRβ imaging on both
macrophage phenotypes (Silvola et al. 2018). Another study conducted by Schniering et al. demonstrated a good correlation between the uptake of the tracer $[^{18}\text{F}]$AzaFol and FRβ expression by macrophages in a lung fibrosis mice model (Schniering et al. 2019). Blocking studies using folic acid showed a significantly reduction in $[^{18}\text{F}]$AzaFol uptake in the fibrotic lung. However, all imaging studies were based on ex vivo analysis and static image acquisition. Therefore, the authors suggest that a dynamic PET scan should be performed in the following experiments where correction for changes in the pulmonary blood flow could be done to avoid the possible non-specific accumulation of $[^{18}\text{F}]$AzaFol in the pulmonary disease model. Despite the limitations presented in this study, $[^{18}\text{F}]$AzaFol is currently being evaluated in early-phase clinical studies in patients with ovarian or lung cancer (https://clinicaltr...
The first-in-man dosimetry studies of $^{18}$F\textsubscript{AzaFol} demonstrated suitable dosimetry outcomes for six patients presenting lung adenocarcinoma, resulting in an estimated effective dose of $18.0 \pm 2.6$ μSv/MBq. The highest absorbed doses found were in the liver, kidneys, bladder, and spleen ($51.9 \pm 16.4$, $45.8 \pm 8.3$, $39.1 \pm 16.8$, and $35.4 \pm 39.7$ μGy/MBq, respectively) whereas tumor presented an average of $34.8 \pm 17$ μGy/MBq. Although favorable dosimetry outcomes were observed, this study was conducted with only few lung cancer patients. Therefore, further investigation using $^{18}$F\textsubscript{AzaFol} is warranted to confirm these results.

Other folate-based tracers, such as $^{68}$Ga\textsubscript{NOTA}-folate and $^{18}$F\textsubscript{AlF-NOTA-folate-PEG}$\subscript{12}$, were recently developed and presented satisfactory results in a human epidermal carcinoma xenograft mouse model, with low accumulation in the liver and high target specificity (Brand et al. 2017; Chen et al. 2017). Chen et al. reported similar biodistribution results for $^{18}$F\textsubscript{AlF-NOTA-folate-PEG}$\subscript{12}$ and the clinically applied SPECT imaging agent $^{99m}$Tc\textsubscript{EC20} (Chen et al. 2017). The pharmacokinetic profile of $^{18}$F\textsubscript{Al-NOTA-PEG}$\subscript{12}$-folate was improved by raising its hydrophilicity, leading to a lower liver uptake, less background and consequently a better target-to-background contrast for detection of hepatic cancer (Chen et al. 2017). In another study conducted by Brand et al., similar biodistribution results between $^{68}$Ga\textsubscript{NOTA}-folate and $^{99m}$Tc\textsubscript{EC20} were observed. However, $^{68}$Ga\textsubscript{NOTA}-folate had a lower liver uptake and faster blood clearance than $^{99m}$Tc\textsubscript{EC20}, making it a promising candidate for further evaluation (Brand et al. 2017). Chandrupatla et al. used $^{18}$F\textsubscript{fluoro-PEG}-folate for the detection of systemic inflammation in the liver and spleen of arthritic rats. The tracer was also used for methotrexate treatment monitoring. After the anti-inflammatory treatment, a twofold lower uptake was observed in the liver and spleen of arthritic rats. The authors attributed these results to the reduction of activated macrophages as a result of the drug therapy (Chandrupatla et al. 2018). In addition, $^{18}$F\textsubscript{fluoro-PEG}-folate showed fast tracer uptake ($\sim 1$ min) in inflamed joints and fast washout from blood of patients presenting rheumatoid arthritis in the first in man study (Verweij et al. 2020). $^{18}$F\textsubscript{fluoro-PEG}-folate demonstrated significant higher target-to-background uptake ratio in joints ($3.5 \pm 2.2$) when compared to $^{11}$C\textsubscript{PK11195} ($1.7 \pm 0.6$). However, the study comparing these tracers was not performed in the same patients and therefore, a head to head comparison was not possible which may interfere in the true tracers comparison.

Overall, folate-based PET tracers might be a good approach for general TAM imaging since folate receptors are expressed by both macrophage phenotypes. Among the tracers described in this section, $^{18}$F\textsubscript{AzaFol} is the only tracer that is under evaluation in humans presenting cancer.

Arginase

Arginase is an enzyme that catalyzes the hydrolysis of L-arginine to L-ornithine and urea. It is present in two isoforms: type I (Arg1), which is mainly expressed in the liver, and type II (Arg2), which is expressed in virtually all tissues. Arg1 is involved in the production of urea for ammonia clearance and in the synthesis of L-ornithine. Arg2 regulates the synthesis of L-ornithine in other tissues (Gonçalo et al. 2020; Grzywa et al. 2020). Arginase levels are negatively correlated with the activity of neuronal, endothelial and inducible nitric oxide synthases (nNOS/eNOS/iNOS) (Gonçalo et al. 2020; Rath...
L-arginine is a precursor for the production of nitric oxide (NO) and consequently arginase and NO synthases compete for the same substrate (Gonçalo et al. 2020; Rath et al. 2014; Thomas and Mattila 2014). Oxidative and inflammatory signaling pathways may disturb the arginase/NO physiological equilibrium. Overexpression of arginase results in a decrease in NO levels and an increase in proline and polyamine levels, which have been related with cardiovascular, inflammatory and immune-mediated pathologies. More importantly, arginase is upregulated mainly by myeloid cells in the TME at the early stages of tumor development and it is associated with poor outcomes. In addition to being expressed by tumor-infiltrating cells, arginase is also known to be expressed in some tumor cells (Grzywa et al. 2020). Arginase overexpression stimulates tumor cell proliferation and evasion from the immune system. Inhibition of arginase would direct L-arginine metabolism towards the NO pathway, promoting inhibition of tumor response, infiltration of M1-like macrophages and the repolarization of M2-like to M1-like macrophages in the TME, which results in immune stimulation and consequently anti-tumor activity (Gonçalo et al. 2020; Grzywa et al. 2020). Thus, inhibition of immunosuppressive functions of arginases has been explored in the treatment of cancer using arginase inhibitors.

Arginase inhibitor-based tracers have not been extensively explored yet. Recently, our research group developed two PET tracers targeting arginase, \([^{18}F]FMARS\) and \([^{18}F]\)FBMARS (Fig. 6) (Clemente et al. 2021). PET imaging and biodistribution studies in mice bearing a PC3-xenograft demonstrated arginase-mediated uptake. PET scans of the xenograft animal model demonstrated a high tracer uptake in PC3 tumors. Tracer uptake was significantly reduced by ca. 60% when (2S)-amino-6-boronohexanoic acid (ABH, an arginase inhibitor) was co-injected, which confirms tracer specificity. Since \([^{18}F]\)FBMARS displayed almost twofold higher tumor uptake than \([^{18}F]FMARS\) (Fig. 6), with a significantly blocking (ca. 70%) by ABH, and presented tumor-to-organ ratios higher than two in ex vivo biodistribution studies, \([^{18}F]\)FBMARS was suggested to be the more suitable tracer to further be evaluated towards application in humans (Clemente et al. 2021).

**Conclusions**

Immunotherapies targeting TAMs seem to be an attractive strategy to decrease tumor progression. Several drugs have emerged in the last decade that could be applied to those patients that usually do not respond to common therapies. The assessment of TAM phenotype is important for patient stratification. Molecular imaging techniques to assess the expression of specific receptors by the TAM have been used to better characterize the tumor profile. PET imaging of the tumor with specific ligands for biomarkers of TAM might help to predict and monitor the response to TAM-targeting therapies.

Several biomarkers on TAM have been already evaluated as target for the assessment of TAMs with PET (Table 1). Several biomarkers presented in this review are expressed by both the M1 and the M2 macrophage phenotypes, in particular CSF-1R, CD68, CCR2, and FRβ. Although these markers are not phenotype selective, they still remain important targets to evaluate the total TAM population in the TME. These macrophage markers are highly expressed in several types of cancer and have been investigated as potential targets for treatment with specific inhibitors (Zhou et al. 2020; Lubowicka
et al. 2018; Kurahara et al. 2012; Jamiyan et al. 2020). So far, PET tracers, such as \([11C]GW2580\) (CSF-1R), \([64Cu]Cu@CuOx-ELCi\) (CCR2), and \([18F]AzaFol\) (folate receptor), have shown potential as radiopharmaceuticals for general TAM assessment. Although high infiltration of macrophages in the TME is correlated to a poor patient prognosis (Poh and Ernst 2018; Chen et al. 2019), the phenotype is important for the immunotherapeutic approach to be selected. As mentioned previously, the M1-like phenotype is related to a better prognosis and the M2-like phenotype to a worse prognosis (Ngambenjawong et al. 2017), making the latter a potential target for tumor regression. So far, PET tracers have been developed for only three targets that are specifically expressed by macrophages of the M2 phenotype, in particular CD206, CD163, and arginase, whereas no PET tracers for targets specifically expressed by M1-like macrophages were found. Among the M2 specific makers reported, the CD206 has already been considered a specific marker for M2 phenotype for many years. Recently, arginase was also proposed to be a potential M2-selective marker, since it is highly expressed by the M2 macrophage phenotype in tumors and does not present expression by M1 macrophages (Cassetta and Pollard 2018). It is important to highlight that M2-type macrophages are also present to some extent under normal conditions (Kambara et al. 2015; Veremeyko et al. 2018; Qi et al. 2016), which could give rise to a small basal, non-disease related signal. A few
potential PET tracers for CD206 have demonstrated suitable properties that warrant further evaluation. Among them, $[^{68}\text{Ga}]{\text{Ga-NOTA-anti-MMR-Sdab}}$ (CD206 receptor) can be highlighted due to the demonstrated good selectivity and safe dosimetry in animals, and therefore, may be a step closer to be available for the clinical trials comparing to others. In addition, $[^{18}\text{F}]{\text{FBMARS}}$ presented high specificity for arginase in a tumor-bearing mouse model. However, despite being presented as a potential target to assess M2-macrophages, the arginase expression might be also stimulated by tumor cells and therefore, $[^{18}\text{F}]{\text{FBMARS}}$ does not present selectivity for M2-macrophages tracking (Thomas and Mattila 2014). In contrast, the increased arginase expression provided by both cells above-mentioned in the TME might lead $[^{18}\text{F}]{\text{FBMARS}}$ to become a suitable PET tracer for arginase inhibitor therapies.

Additionally, despite CD163 receptor being considered a selective marker for M2-type macrophages, no suitable PET tracer has been developed until now. Likewise, no specific PET tracer for the M1-TAM phenotype was developed so far. This observation might be due to the fact that most markers on M1-type macrophages (e.g. the CD80 and CD86 receptor) are not specific for macrophages, as they are also expressed by other cells, such as antigen-presenting cells (e.g. dendritic cells, and B cells) [82]. Another explanation is the higher interest of researchers for the M2-phenotype, since it is instrumental in the worse patient prognosis and thus a more attractive drug target.

Interestingly, the majority of specific PET tracers for TAMs were only evaluated preclinically (Table 1), except for the two folate tracers $[^{18}\text{F}]{\text{AzaFol}}$, which is a general TAM tracer that is being evaluated in lung and ovarian cancer in clinical trials, and $[^{18}\text{F}]{\text{fluoro-PEG-folate}}$ folate that was tested in first in man study with patients presenting rheumatoid arthritis. The translation from preclinical to clinical studies is a lengthy process that may be influenced by several factors, including the fact that preclinical models are not able to fully mimic human disease [83]. In addition, radiotracers in early preclinical development usually fail because they do not present enough specificity or stability in vivo. Nonetheless, TAM targets need to be further explored, and the already existing PET tracers further tested in tumor models and subsequently in patients.

To summarize, imaging TAMs using PET tracers is still in its infancy, but seems to be a potential approach for early tumor characterization, response prediction and treatment monitoring, mainly in patients who present tumor-promoting macrophages in the TME. PET imaging may thus provide a better impression of the physiology and anatomy of tumors and can guide physicians towards more tailored treatments for patients presenting TAM infiltration.

**Abbreviations**

- ABH: 2-(S)-amino-6-boronohexanoic acid
- ApoE: Apolipoprotein E
- Arg: Arginase
- BBB: Blood–brain barrier
- $^{11}\text{C}$: Carbon-11
- CCR2: C–C chemokine receptor type 2
- CCL2: Chemokine (C–C Motif ) ligand 2
- CD: Cluster of differentiation
- COX-2: Cyclooxygenase-2
- CSF-1R: Colony stimulating factor 1 receptor
- $^{64}\text{Cu}$: Copper-64
- DHFR: Dihydrofolate reductase
- $^{18}\text{F}$: Fluorine-18
- FA: Folic acid
- Fab: Antibody fragment
- Fc: Fragment crystallizable region
- FR: Folate receptor
- $^{68}\text{Ga}$: Gallium-68
- $^{68}\text{Ge}$: Germanium-68
- Hp-Hb: Haptoglobin-hemoglobin
- IC50: Half maximal inhibitory concentration
- IFN-γ: Interferon-gamma
- IL: Interleukin
- iNOS: Inducible nitric oxide synthase
- KB: Human epithelial cancer cell
- LPS: Lipopolysaccharide
- MBq: Megabecquerel
- MMR: Macrophage mannose receptor
- Nb: Nanobody
- OxLDL: Oxidized low-density protein
- PET: Positron emission tomography
- ROS: Reactive oxygen species
- sdAb: Single-domain antibody
- SPECT: Single-photon emission computerized tomography
- SR: Scavenger receptor
- SRCR: Cysteine-rich scavenger receptors
- TAM: Tumor-associated macrophages
- THF: Tetrahydrofolate
- TME: Tumor microenvironment
- TNF: Tumor necrosis factor
- μGy: Microgray
- μSv: Microsievert
Acknowledgements
Not applicable.

Author contributions
BF, PKF, CL, and LRN contributed to the research and writing of this review. BF was the major contributor in this manuscript. CMMJ, IFA, PHE, and EFJV reviewed the manuscript. All authors read and approved the final manuscript.

Funding
No funding was received.

Availability of data and materials
Not applicable. No dataset was generated or analysed for this study and therefore, the data sharing is not applicable.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, P.O. Box 30 001, 9700 RB Groningen, The Netherlands. 2 Graduate Program in Biomedical Gerontology, School of Medicine, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, Brazil. 3 Laboratory of Cellular Biophysics and Inflammation, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, Brazil. 4 Laboratory of Pediatric Physical Activity, Infant Center, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, Brazil.

Received: 8 February 2022   Accepted: 20 April 2022

Published online: 08 May 2022

References
Biodistribution, tumor detection, and radiation dosimetry of [18F]-AZAFOL as positron emission tomography (PET) tracer in folate receptor positive cancer imaging. 2017 [cited 28 Jul 2021]. https://clinicaltrials.gov/ct2/show/NCT03242993.

Baggiolini M. Chemokines and leukocyte traffic. Nature. 1998;392(6676):565–8.

Bialke B, et al. PET/CT and MR imaging biomarker of lipid-rich plaques using [64Cu]-labeled scavenger receptor (CD68-Fc). Int J Cardiol. 2014;177(1):287–91.

Blykers A, et al. PET imaging of macrophage mannose receptor–expressing macrophages in tumor stroma using 18F-radiolabeled camelid single-domain antibody fragments. J Nucl Med. 2015;56(8):1265–71.

Boss SD, et al. Reduced 18F-folate conjugates as a new class of PET tracers for folate receptor imaging. Bioconj Chem. 2018;29(4):1119–30.

Boutilier AJ, Elsawa SF. Macrophage polarization states in the tumor microenvironment. Int J Mol Sci. 2021;22(13):6995.

Brand C, et al. Development of a new folate-derived Ga-68-based PET imaging agent. Mol Imaging Biol. 2017;19(5):534–61.

Cannarile MA, et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer. 2017;5(1):1–13.

Cassette L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17(12):887–904.

Cendrowicz E, et al. The role of macrophages in cancer development and therapy. Cancers. 2021;13(8):1946.

Chandrupatla DMGH, et al. Imaging and methotrexate response monitoring of systemic inflammation in arthritic rats employing the macrophage PET tracer [18F] fluoro-PEG-folate. Contrast Med Mol Imaging. 2018;2018:8092781.

Chen Q, et al. Folate-PEG-NOTA-AI18F: a new folate based radiotracer for PET imaging of folate receptor-positive tumors. Mol Pharm. 2017;14(12):4353–61.

Chen Y, Tan W, Wang C. Tumor-associated macrophage-derived cytokines enhance cancer stem-like characteristics through epithelial–mesenchymal transition. Onco Targets Ther. 2018;11:3817.

Chen Y, et al. Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019;26(1):1–13.

Chistiakov DA, et al. The impact of interferon-regulatory factors to macrophage differentiation and polarization into M1 and M2. Immunobiology. 2018;223(1):101–11.

Cho PS, et al. Synthesis and evaluation of 68 Ga-HBED-CC-EDBE-folate for positron-emission tomography imaging of overexpressed folate receptors on CT26 tumor cells. J Label Compd Radiopharm. 2018;61(1):4–10.

Clemente GS, et al. Mapping arginase expression with 18F-fluorinated late-generation arginase inhibitors derived from quaternary γ-amino acids. J Nucl Med. 2021;62(8):1163–70.

Dei MB, et al. Modulating macrophage polarization through CCR2 inhibition and multivalent engagement. Mol Pharm. 2018;15(7):2721–31.
Eichendorff S, et al. Biodistribution and PET imaging of a novel [68 Ga]-anti-CD163-antibody conjugate in rats with collagen-induced arthritis and in controls. Mol Imaging Biol. 2015;17(1):87–93.

English SJ, et al. CR2R positron emission tomography for the assessment of abdominal aortic aneurysm inflammation and rupture prediction. Circ Cardiovasc Imaging. 2020;13(5):e009889.

Fischer JA, Rossetti S, Sacchi N. CSF1R (colony stimulating factor 1 receptor, formerly McDonough feline sarcoma viral (V-FMS) oncogene homolog). http://AtlasGeneticsOncology.org (2009): 120.

Galli F, et al. Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. J Exp Clin Cancer Res. 2020;39:1–21.

Gonçalo SC, et al. Arginase as a potential biomarker of disease progression: a molecular imaging perspective. Int J Mol Sci. 2020;21(15):S291.

González H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32(19–20):1267–84.

Graversen JH, Moestrup SK. Drug trafficking into macrophages via the endocytic receptor CD163. Membranes. 2015;5(2):228–52.

Grzywa TM, et al. Myeloid cell-derived arginase in cancer immune response. Front Immunol. 2020;11:938.

Hao Q, Vadgama JV, Wang P. CCL2/CCR2 signaling in cancer pathogenesis. Cell Commun Signal. 2020;18:1–13.

Horti AG, et al. PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). Proc Natl Acad Sci. 2019;116(5):1686–91.

Ivashkiv LB. IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018;18(9):545–58.

Jamshiy S, et al. CD68-and CD163-positive tumor-associated macrophages in triple negative cancer of the breast. Virochows Arch. 2020;477(6):767–75.

Jeong H, et al. Tumor-associated macrophages as potential prognostic biomarkers of invasive breast cancer. J Breast Cancer. 2019;22(1):38–51.

Jung J, Zeng Hu, Horng T. Metabolism as a guiding force for immunity. Nat Cell Biol. 2019;21(1):85–93.

Kambara K, et al. In vivo depletion of CD206+ M2 macrophages exaggerates lung injury in endotoxemic mice. Am J Pathol. 2015;185(1):162–71.

Kim EJ, et al. Novel PET imaging of atherosclerosis with 68Ga-labeled NOTA-neomannosylated human serum albumin. J Nucl Med. 2016;57(11):1792–7.

Kurahara H, et al. Clinical significance of folate receptor β-expressing tumor-associated macrophages in pancreatic cancer. Ann Surg Oncol. 2012;19(7):2264–71.

Li C, et al. Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer. J Immunotherapy Cancer. 2021;9(1):e001341.

Lubowicka E, et al. Plasma chemokine CCL2 and its receptor CCR2 concentrations as diagnostic biomarkers for breast cancer patients. BioMed Res Int. 2018;2018:2142390.

Malyshiev Y, Malyshiev Y. Current concept and update of the macrophage plasticity concept: intracellular mechanisms of reprogramming and M3 macrophage “switch” phenotype. Biomed Res Int. 2015;2015:341308.

Mir MA. Developing costimulatory molecules for immunotherapy of diseases. Cambridge: Academic Press; 2015.

Mukherjee S, et al. The yin and yang of imaging tumor associated macrophages with PET and MRI. Theranostics. 2019;9(25):7730.

Murphy K, Weaver C. Janeway’s immunobiology. New York: Garland Science; 2016.

Newman AC, Maddocks ODK. One-carbon metabolism in cancer. Br J Cancer. 2017;116(12):1499–504.

Ngambenjawong C, Gustafson HH, Pun SH. Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev. 2017;114:206–21.

Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49–61.

Pilleron S, et al. Global cancer incidence in older adults, 2012 and 2035: a population-based study. Int J Cancer. 2019;144(1):49–58.

Poh AR, Ernst M. Targeting macrophages in cancer: from bench to bedside. Front Oncol. 2018;8:49.

Pound P, Ritskes-Hoitinga M. Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail. J Transl Med. 2018;16(1):1–8.

PrabhuDas MR, et al. A consensus definitive classification of scavenger receptors and their roles in health and disease. J Cancer Res. 2017;23(4):876–84.

Pyonteck SM, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19(10):1264–72.

Qi L, et al. IL-10 secreted by M2 macrophage promoted tumorigenesis through interaction with JAK2 in glioma. Oncotarget. 2016;7(44):71673.

Quail DF, Joyce JA. Molecular pathways: deciphering mechanisms of resistance to macrophage-targeted therapies. Clin Cancer Res. 2017;23(4):876–84.

Rath M, et al. Metabolism via arginase or nitric oxide synthase: two competing arginine pathways in macrophages. Front Immunol. 2014;5:532.

Russell DG, Huang Lu, VanderVen BC. Immunometabolism at the interface between macrophages and pathogens. Nat Rev Immunol. 2019;19(5):291–304.

Schniering J, et al. 18F-AzaFol for detection of folate receptor-β positive macrophages in experimental interstitial lung disease—a proof-of-concept study. Front Immunol. 2019;10:2724.

Shen J, et al. Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies. Oncotarget. 2016;9(4):4485.

Silva RA, et al. CTHRRSVVC peptide as a possible early molecular imaging target for atherosclerosis. Int J Mol Sci. 2016;17(9):1383.
Silvola JMU, et al. Aluminum fluoride-18 labeled folate enables in vivo detection of atherosclerotic plaque inflammation by positron emission tomography. Sci Rep. 2018;8(1):1–15.

Skytthe MK, Graversen JH, Moestrup SK. Targeting of CD163+ macrophages in inflammatory and malignant diseases. Int J Mol Sci. 2020;21(15):5497.

Sosnik A. From the “magic bullet” to advanced nanomaterials for active targeting in diagnostics and therapeutics. In: Biomedical applications of functionalized nanomaterials. Elsevier, 2018. 1–32.

Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Tahara N, et al. 2-deoxy-2-[18 F] fluoro-d-mannose positron emission tomography imaging in atherosclerosis. Nat Med. 2014;20(2):215–9.

Tanzey SS, et al. Synthesis and initial in vivo evaluation of [11C] AZ683—a novel PET radiotracer for colony stimulating factor 1 receptor (CSF1R). Pharmaceuticals. 2018;11(4):136.

Tap WD, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med. 2015;373(5):428–37.

Thomas AC, Mattila JT. “Of mice and men”: arginine metabolism in macrophages. Front Immunol. 2014;5:479.

Tsai W-T, Wu AM. Aligning physics and physiology: Engineering antibodies for radionuclide delivery. J Labelled Compd Radiopharm. 2018;61(9):693–714.

Tsaur I, et al. CCL2 chemokine as a potential biomarker for prostate cancer: a pilot study. Cancer Res Treat. 2015;47(2):306. Valero JG, et al. The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma. Leukemia. 2021;10:1–15.

Veremeyko T, et al. Early growth response gene-2 is essential for M1 and M2 macrophage activation and plasticity by modulation of the transcription factor CEBPβ. Front Immunol. 2018;9:2515.

Verweij NJF, et al. First in man study of [18 F] fluoro-PEG-folate PET: a novel macrophage imaging technique to visualize rheumatoid arthritis. Sci Rep. 2020;10(1):1–10.

Xavier C, et al. Clinical translation of [68 Ga] Ga-NOTA-anti-MMRI-sdAb for PET/CT imaging of protumorigenic macrophages. Mol Imaging Biol. 2019;21(5):898–906.

Yan H, et al. Enhanced CD163+/CD68+ ratio at tumor invasive front is closely associated with aggressive phenotype and poor prognosis in colorectal cancer. Int J Biol Sci. 2019;15(5):984.

Zhang S-Y, et al. Tumor-associated macrophages: a promising target for a cancer immunotherapeutic strategy. Pharmacol Res. 2020;161:105111.

Zhang Y, et al. Tumor-associated macrophages: recent insights and therapies. Front Oncol. 2020;10:188.

Zhou J, et al. PET imaging of colony-stimulating factor 1 receptor: a head-to-head comparison of a novel radioligand, 11C-GW2580, and 11C-CPPC, in mouse models of acute and chronic neuroinflammation and a rhesus monkey. J Cereb Blood Flow Metab. 2021;41(9):2410–22.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.